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that the launch of the NHI system. To improve the system even further, future chal-
lenge will be our motive to reform and also lead us to a new stage in health care.
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Glioblastoma (GBM) is an aggressive, high-grade glioma characterized by rapid 
growth and microvascular proliferation. Tumors are typically localized to the cer-
ebrum and rarely distantly metastasize. Worsening of neurocognitive symptoms is 
observed with GBM progression, and can significantly impact patient function and 
quality of life. Current treatments are non-curative and have not demonstrated 
an increase in overall survival. Progression-free survival (PFS) is a common pri-
mary endpoint in clinical trials of GBM therapies; however, it is important in this 
patient population to quantify how time without disease progression benefits 
patients. Recent decisions by health authorities and payers suggest an increasing 
trend towards the need for evidence of patient-centered endpoints, particularly for 
reimbursement decision-making. Assessment of neurocognitive deterioration due 
to GBM progression during the clinical trial period is challenging given the need to 
sensitively assess a range of symptoms that may manifest due to lesions in differ-
ent regions of the brain. A disease model, or conceptual framework, is needed to 
ground decision-making around choice of instruments, endpoints, and schedules 
of symptom assessments, thus ensuring measurement of the most patient and bio-
logically relevant symptoms. The framework presented here outlines the biological 
processes that contribute to non-focal symptoms of GBM, such as headache, as well 
as focal symptoms, such as visual disturbances, changes in memory, or loss of verbal 
expression. Considerations and challenges in assessing neurocognitive symptoms in 
GBM patients utilizing existing tools and methodologies are reviewed and identified.
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Developed countries have largely achieved universal health care coverage, while 
many developing countries are implementing steps to increase health care cover-
age. While the objective is the same, the health care systems and policies across 
countries differ across countries leading to different levels of access to medicines. 
To understand which systems and policies can lead to better access, we need a 
measure to evaluate how well countries do in terms of providing access to medi-
cine for their populations. In this paper, we develop a Country Access to Medicines 
Index that compares and ranks countries on access to medicine outcomes. This 
index is based on five pillars – ease of accessibility to health care workers and 
facilities, awareness of disease diagnosis and treatment, availability of medicines, 
affordability of medicines and adherence to right treatment. We identify key vari-
ables in each of these pillars and compare and rank 30 countries with more than 
60% of the world’s population on each of these variables, at an aggregate level 
on each pillar, and overall. We draw upon IMS data as well as international and 
country level sources to obtain the data needed for the measures. We then look at 
the health systems and policies in these countries to identify features that lead to 
better performance on the index. We find that five broad factors can help explain 
access to medicines performance. First is the level of financing of health care, espe-
cially reimbursement coverage. Second is a structured and transparent pricing and 
patient access system that prioritises resource allocation to high need diseases and 
patients and sets economically justifiable prices. Third is the level of development 
of health care infrastructure. Fourth, is the provider and pharmacy incentives that 
promote appropriate use of medicine. And finally, a system that ensures the proper 
implementation of health policy initiatives.
PHP135
tHe inFluential Patient: role oF Patient oPinion leaders on 
PHarmaCeutiCal researCH and develoPment, HealtH PoliCy, and 
CommerCialization
Ko J.1, Godley P.J.2
1Scott & White Health Plan/Univ of Texas at Austin/Novartis Pharmaceuticals Corp., Temple, TX, 
USA, 2Scott & White Health Plan, Temple, TX, USA
The increasing adoption of Internet and social media have facilitated the emergence 
of patient opinion leaders (POLs). These influential individuals are living with a 
chronic disease and are writing about their experiences on Internet blogs and social 
media websites. Popular and highly-trusted patients are labeled as POLs because 
their work influences the decision-making of other patients. Top POLs have tens 
of thousands of followers who subscribe to their websites, blogs, and online social 
media accounts. POLs usually focus on one therapeutic area and provide disease-
related information, treatment options, and emotional support to other patients. 
Additionally, some POLs are health activists who help shape health policy and 
provide input into clinical trial design including endpoint development. As health 
care increases its focus to center around the individual patient, pharmaceutical 
companies and government agencies will seek out POLs for their personal perspec-
tives. A formal methodology to measure the influence and reach of POLs has yet 
to be established. Their influence on the Internet can be determined by the size of 
their audience (e.g., Twitter followers), relevancy of posted content to the disease 
state of interest, frequency of posted content, and perceived trustworthiness based 
on various scales (e.g., Google’s PageRank algorithm). By characterizing and index-
ing POLs, interested stakeholders can easily engage with them to incorporate the 
patient’s voice into clinical trials, market research, health policy, and marketing. As 
an example, researchers can capture and leverage the large audience of an influen-
tial POL to recruit patients for a clinical trial or to garner feedback on the endpoints 
of a clinical trial from the patients’ perspectives. This paper’s objective is to evaluate 
teria decision analysis. ConClusions: These and other methods may be used by 
CONITEC’s assessment, approaching the issues of efficiency and equity in decision 
making. Thus, is expected to contribute to the development and application of these 
decision-support tools and to improve the criteria of Ministry of Health for deciding 
which technologies to fund.
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objeCtives: An application of predictive and pharmacogenetic tests in appoint-
ment of targeted anti-cancer therapy and predict response to treatment. Considering 
significant practical necessity of molecular-genetic methods for health care and 
high cost, it is important to evaluate these technologies in terms of health econom-
ics. Methods: A systematic review of articles has been conducted using databases 
PubMed, The Cochrane Library, and published reports and market reviews. Results: 
In the period from 2007 to 2012 it is estimated the world market in vitro diagnostic 
(IVD) is increasing due to the development of molecular diagnostic tests and rapid 
test kits. Experts point out that a key factor in the growth segment of molecu-
lar diagnostics in recent years has been precisely the emergence of new oncology 
tests to prescribe targeted therapy. At the moment, in IVD diagnostics segment in 
Russia market is forecasted growth rate for 2014 at 10-20%. Price of tests for oncol-
ogy biomarkers depends on the technology: - for most routine immunological and 
chemical tests is between 10 and 15 USD; - for molecular genetic tests costs varies 
from 40 to 4000 USD per procedure. In addition to practiced in Russian Federation 
KRAS- and EGFR-testing, in this review discussed the practical value of: testing 
EML4-ALK mutation for crizotinib in non-small lung cancer; BRAF V600E-testing 
for vemurafenib in melanoma; HER2/neu-testing for trastuzumab in breast cancer. 
Thus, the Russian segment of the cancer diagnostics market is the fast-growing 
market. However, the analysis of the literature showed that until that time in the 
Russian Federation was not conducted clinical and economic evaluation of these 
medical technologies. ConClusions: The analysis revealed that evaluation of diag-
nostic test systems in oncology from the point of view of health economics of the 
Russian Federation is a topical field for research and requires a rigorous analysis.
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Transitional care management programs have been shown to improve medication 
adherence, elevate patient comprehension of their disease state, increase patient 
satisfaction, and reduce preventable readmission rates due to certain diagno-
ses (e.g., congestive heart failure). However, the true value of such programs has 
recently become more important to key health care decision makers as the United 
States transitions away from a fee for service model to a value based payment 
system. The provision of medication therapy management is a vital component 
of many transitional care management programs, yet the cost effectiveness of 
pharmacist interventions remains difficult to quantify. The inability to assign 
a universally accepted economic value to such transitional care programs has 
hindered the implementation of a sustainable business model for such services; 
despite the positive impact on patient health outcomes. This paper explores the 
unique challenges a national post-acute health care network faced while attempt-
ing to incorporate cost-effective clinical pharmacy services into its transitional 
care management programs. First, we discuss the impact of various strategies to 
stratify patient readmission risk in different settings of care. Second, the challenge 
to participate in a risk-sharing model in a health system still driven by patient 
choice is investigated. Finally, we evaluate the published methods used to quantify 
the economic impact clinical pharmacist interventions. Our assessment of the 
above topics is applied to three case studies; each located in a distinct region of 
the United States and with unique approaches to the provision and reimburse-
ment of health care. Our conclusions support the need for additional investment 
into the value of transitional care pharmacy services throughout the post-acute 
care continuum.
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The National Health Insurance (NHI) Program in Taiwan is a mandatory govern-
ment-run social insurance system cover 99% of the population. Since its inception 
in 1995, NHI has been facing the challenges of rapid increase on health care costs, 
particularly in 1998; nominal growth rate of NHI costs reached 11.4% per year. So 
many strategies have been introduced in controlling costs and in improving qual-
ity of care, and the Second-Generation NHI was implemented in January 1, 2013. 
Among them the pharmaceutical benefits and expenditures strategies were the 
most important reforms. The drug cost of NHI was about 4.4 billion USD in 2012, 
nearly 25% of total health insurance expenditure, and drug cost per capita was 204 
USD. Over 18,000 drugs were listed in the Drug Price List, and average new drugs 
listed time was 144 days. The average growth rate on drug fees was 4.8% for recent 10 
years. Many strategies had been introduced to control drug costs, such that : (1) Drug 
Price List was revised continuously based on setting reference prices for the drugs 
with same ingredients .The price was adjusted 9 times from 2000 to 2011. (2) “Drug 
Expenditure Target” policy into practice in January 1, 2013. It control unreasonable 
drug fees rising, and make drug policy predictable to the pharmaceutical industrial 
in Taiwan. (3) other reform such as focused on efficient pharmaceutical benefits 
and payment systems, equity in pharmaceutical transactions, public participation 
and information transparency. However, these biggest reform are now high hopes 
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and untreatable, it may preclude them from seeking treatment. Third, MHLt posits 
that KABs collectively determine HSB unidirectionally. A bidirectional relationship 
may be more appropriate because patient behavior and human decision-making 
are fluid and constantly changing. In addition, this bidirectional relationship allows 
for a period of assessment necessary for patients to weigh their KABs against the 
current situation. Lastly, another needed component is resource availability (e.g., 
access to care and insurance status). In conclusion, as the first theory to conceptual-
ize literacy regarding mental health, the MHLt laid the foundation for exploring the 
relationship between KABs and HSB however, several improvements and additions 
to the theory may advance this body of work.
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The expiry dates mentioned on the medicines are considered inviolable by the 
patients. Given by the manufacturer and approved by the highest regulatory agen-
cies of a country, expiry date is considered as the ultimate safeguard to ensure the 
safety of the medicine being used by the patients. Exaggerated expiration dates 
pose economic burden on the health care system of a country, the effect being 
more significant in the underdeveloped and developing economies. In developed 
countries these issues have been addressed by using pharmacoeconomic tools like 
a. Cost- minimization analysis b. Cost- effective analysis c. Cost- utility analysis d. 
Cost- benefit analysis. The outcome of the studies conducted under the Shelf Life 
Extension Program by FDA clearly indicate that pre-occupation with the safety 
issues has resulted in all stake-holders being too conservative about the expiry 
dates. This results in the wasteful disposal of the drugs which are still therapeuti-
cally effective after their labelled expiry dates. This article discusses the general 
societal notions about the expiry dates of the drugs, the procedures being generally 
followed by pharmaceutical industries to give the expiration dates to the drugs, 
cases where the expiry dates have been extended by the regulatory agencies them-
selves and a testing program that started as an Air Force initiative in collaboration 
with FDA and saved American taxpayers millions of dollars. The article also recom-
mends the scientific course that may be taken towards a more pragmatic approach 
towards the expiry date labelling.
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objeCtives: At present, the digital divide is generally considered a problem of 
access. This perspective is perpetuated by several assumptions regarding the 
availability, usability, and content of current health information and technological 
communications (ICT) promoting chronic care management. These biases serve to 
limit benefits of health technology innovation among the medically underserved 
or at-risk patient populations. Most prominent, the myths of ready access and sus-
tained engagement are presented - both of which differentially expose already 
vulnerable groups to fewer technological advances to improve patient care readily 
available to other groups in addition to poorer quality information to base medi-
cal decisions upon, thus reinforcing disengagement and potentially widening the 
divide. Methods: By drawing on a range of literatures, including health com-
munications, medical informatics, social determinants of health, health behav-
ior and promotion, the purpose of this work is to deconstruct the divide, describe 
its importance and impact in health care settings, in an effort to improve under-
standing of its role in medication adherence and patient engagement in order to 
inform tailored intervention development. Results: Specifically, this conceptual 
work describes elements and challenges assumptions driving the divide in order 
to: expand understanding of the digital divide in practice, recognize important 
patient groups are being negatively impacted, and increase awareness of eHealth 
literacy and efficacy that may directly impact adherence and patient engagement. 
Examples of patient-centered technology tools are provided, such as the Personal 
Health Record (PHR), illustrating the potential for reducing as well as increasing the 
digital divide; if features of the divide are not considered when developing techno-
logically-based behavioral interventions, those relying on health ICT may serve to 
amplify inequalities in health and health care. ConClusions: Conclusions elu-
cidating the elements upon which patient-centered interventions may be tailored 
appropriately are offered, providing suggestions to inform both population-based 
as well as individual-based health management strategies.
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intRoduCtion: Judicialization of health is the terminology that refers to the sig-
nificant increase in lawsuits (legal queries) aiming to provide drugs and medical 
treatments. In this sense, since the role of the Judiciary is considered essential to 
confirm the social and constitutional rights to health, the legal sentences provoke 
a point of tension for policy-makers and for the government, compelled to ensure 
provisions that are in conflict with the budget established and policies for the 
health care sector. objeCtives: To describe the importance of Health Technology 
Assessment (HTA) in helping to orientate judges, patients, policy-makers and other 
legal actors in lawsuits. Methods: Analytical paper. Results: The evolution of 
medicine requires programmatic bias about the right to health, as always there will 
be new discoveries, new procedures, new diseases or the return of once eradicated 
diseases. Studies on efficacy, safety, effectiveness and cost-effectiveness are the 
main components of the Health Technology Assessment (HTA) field, which can be 
the importance of POLs, to propose a method to measure a POL’s influence, and to 
examine the possible roles of POLs.
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objeCtive: The life sciences and health technology (LSHT) sector is one of the key 
knowledge based area in Quebec. It provides for economic growth, wealth creation 
and quality of life improvement. The LSHT sector has been experiencing important 
changes of its R&D model over the past 5 years, hense modifying resources alloca-
tion. The objective of this analysis was to describe the LSHT in Quebec, look at its 
recent evolution and identify key elements of success contributing to grow this 
sector. Methods: Information, gathered from the Quebec ministry of finance and 
economy, Quebec Institute of Statistics, Statistics Canada, Montréal International, 
US Bureau of Labor Statistics, Eurostat and Europe Innova, was used to develop a 
comparative analysis of the LSHT sector concerning wealth creation and economic 
growth for selected LSHT sub-sector in selected Canadian provinces, US states and 
European regions. The following information was gathered for the analysis: public 
and private employment and salaries (direct and indirect), gross domestic product 
(GDP), concentration of employment. Results: The analysis shows that the LSHT 
sector accounts for 1.5% of Quebec GDP and that employment in this sector gener-
ates more value (+70%) when compared to all the other economic sectors taken 
together. The comparative analysis, based on 35 regions in Europe, United States 
and Canada, shows that Quebec is one of the 3 regions with a diversified LSHT sec-
tor while other regions have specialized in one subsector (biotechnology, medical 
technology, pharma). The results show also that only 22% of regions grew between 
2008-2012. ConClusion: This analysis suggests that the growth of LSHT cannot 
only be explained by the diversity of the subsector activities. The presence of large 
research and health centers as well as collaborative approach could explain the 
success for that growth. Further analysis would be required to measure the impact 
of each of these factors.
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objeCtives: Pharmaceutical stakeholders in Central Eastern Europe (CEE) often 
refer to international evidence from other jurisdictions to express the benefits of 
innovative medicines in cost savings or productivity gain. One of the most fre-
quently cited statements argues that increased expenditure on innovative medi-
cines may be offset by reduced hospital stay or avoided complications. Another 
popular argument is to express the value of modern medicines with the potential 
link between life expectancy and GDP growth. The aim of this research is to evalu-
ate the transferability of the most frequently referred international case studies 
to CEE. Methods: Detailed literature review and appraisal of the transferability 
of these approaches to CEE. Results: CEE countries differ in several important 
aspects from high income countries: the overall health status of the population 
is worse; the price level of health care services is lower, mainly due to lower man-
power costs. On the contrary there is no significant difference in the price level of 
innovative medicines compared to high income countries. As the relative cost of 
hospitalisation is lower than cost of medicines in CEE countries, the cost saving 
potential from avoided hospitalisation and complications is more limited. As an 
average person in CEE countries lives longer than the retirement age, it is difficult 
to judge how additional life-years of inactive populations can increase productivity 
gain and consequently how it may contribute to GDP growth. As increased longev-
ity increases health expenditure, the major benefit of innovative medicines can 
be health gain in CEE. ConClusions: The expectation to control overall health 
expenditure by extensive use of innovative drugs is unrealistic in the CEE region. 
Transferability of real world evidence on the benefits of innovative medicines from 
high income countries to lower income countries is limited.
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Mental illness (MI) is a national problem and over 60% of people who suffer from 
MI do not receive treatment. Understanding factors that may impact treatment 
seeking is important in developing effective intervention programs. Mental Health 
Literacy theory (MHLt) purports that one’s knowledge, attitudes and beliefs (KABs) 
about the following MI domains: 1)causes; 2)recognition; 3)how to seek information; 
and 4)sources of help can predict their help-seeking behaviors (HSB). The purpose 
of this paper is to critically evaluate the predictors and directionality of MHLt. This 
systematic analysis resulted in meaningful alterations to the theory based upon the 
need for the individual’s perspective on MI. MHLt conceptualizes the level of one’s 
literacy from a ‘top down’ approach. If a patient’s KABs are contrary to those of the 
professional community, then the patient is deemed to have low MHL. This approach 
minimizes patients’ experiences and beliefs, and may place the views of the pro-
fessional at odds with that of the patient resulting in disillusionment and distrust 
of the health care system. Second, MHLt neglects the role of prevention and self-
management, which is problematic because if a patient views MI as unpreventable 
